Your browser doesn't support javascript.
loading
Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou, Xinping; Mei, Chen; Zhang, Jin; Lu, Ying; Lan, Jianping; Lin, Shengyun; Zhang, Yuefeng; Kuang, Yuemin; Ren, Yanling; Ma, Liya; Wei, Juying; Ye, Li; Xu, Weilai; Li, Kongfei; Lu, Chenxi; Jin, Jie; Tong, Hongyan.
  • Zhou X; Department of Hematology, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
  • Mei C; MDS Center, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
  • Zhang J; Department of Hematology, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
  • Lu Y; MDS Center, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
  • Lan J; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Lin S; Department of hematology, Yinzhou People's Hospital Affiliated to Medical College of Ningbo University, Ningbo, China.
  • Zhang Y; Department of hematology, Zhejiang Province People's Hospital, Hangzhou, China.
  • Kuang Y; Department of hematology, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, China.
  • Ren Y; Department of hematology, First People's Hospital of Yuhang District, Hangzhou, China.
  • Ma L; Department of hematology, Jinhua People's Hospital, Jinhua, China.
  • Wei J; Department of Hematology, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
  • Ye L; MDS Center, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
  • Xu W; Department of Hematology, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
  • Li K; MDS Center, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
  • Lu C; Department of Hematology, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
  • Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
  • Tong H; MDS Center, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Hematol Oncol ; 38(4): 531-540, 2020 Oct.
Article en En | MEDLINE | ID: mdl-32469434
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Anemia Refractaria con Exceso de Blastos / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Epigénesis Genética / Evolución Clonal Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Anemia Refractaria con Exceso de Blastos / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Epigénesis Genética / Evolución Clonal Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article